Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.23
-26.8%
$0.25
$0.17
$3.93
$743K-0.08130,044 shs20,702 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$2.50
+0.6%
$2.20
$1.20
$17.75
$3.52M0.12616,558 shs3,569 shs
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.65
0.0%
$1.45
$1.10
$43.69
$3.53M-1.62269,388 shs13,661 shs
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
$0.67
-13.9%
$0.62
$0.47
$6.30
$3.24M0.822.40 million shs1.59 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-26.82%-33.34%-10.27%-6.72%-93.17%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
+7.83%0.00%-20.77%+86.47%-85.06%
GRI Bio, Inc. stock logo
GRI
GRI Bio
+12.24%+20.44%+19.57%+26.92%-94.08%
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
+17.37%+19.05%+18.34%-24.76%-79.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
2.1368 of 5 stars
0.04.00.04.60.90.01.9
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
2.29 of 5 stars
3.55.00.00.00.01.70.0
GRI Bio, Inc. stock logo
GRI
GRI Bio
3.1239 of 5 stars
3.55.00.00.01.90.01.3
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
1.0481 of 5 stars
0.05.00.00.02.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
3.00
Buy$10.00300.80% Upside
GRI Bio, Inc. stock logo
GRI
GRI Bio
3.00
Buy$22.001,233.74% Upside
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ATXI, EVAX, ZVSA, and GRI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/27/2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $34.00
4/14/2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$3.34M1.05N/AN/A($1.18) per share-2.11
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/AN/AN/AN/A$7.68 per shareN/A
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
N/AN/AN/AN/A$3.40 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$7.490.01N/AN/A-471.57%-296.50%8/7/2025 (Estimated)
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-$10.57M-$1.16N/AN/AN/A-316.03%-532.72%-78.32%8/13/2025 (Estimated)
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$8.21M-$11.56N/AN/AN/AN/A-275.15%-168.22%8/12/2025 (Estimated)
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
-$9.41MN/A0.00N/AN/AN/A-109.54%-43.95%8/8/2025 (Estimated)

Latest ATXI, EVAX, ZVSA, and GRI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/27/2025Q1 2025
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A
5/15/2025Q1 2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$4.08-$5.80-$1.72-$5.80N/AN/A
5/12/2025Q1 2025
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
-$0.40-$0.73-$0.33-$0.73N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
N/AN/AN/AN/AN/A
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/AN/AN/AN/AN/A
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
N/A
2.01
2.01
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/A
1.41
1.41
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
N/A
0.18
0.18

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
11.04%
GRI Bio, Inc. stock logo
GRI
GRI Bio
33.95%
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
3.91%

Insider Ownership

CompanyInsider Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.80%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
41.64%
GRI Bio, Inc. stock logo
GRI
GRI Bio
0.13%
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
0.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.18 million2.02 millionNot Optionable
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
601.40 million819,000No Data
GRI Bio, Inc. stock logo
GRI
GRI Bio
12.14 million2.14 millionNot Optionable
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
24.77 million4.76 millionNot Optionable

Recent News About These Companies

ZVSA - ZyVersa Therapeutics Inc News - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.23 -0.09 (-26.82%)
As of 07/8/2025 03:15 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Evaxion A/S stock logo

Evaxion A/S NASDAQ:EVAX

$2.50 +0.02 (+0.60%)
As of 09:58 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

GRI Bio stock logo

GRI Bio NASDAQ:GRI

$1.65 0.00 (-0.03%)
As of 09:39 AM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

ZyVersa Therapeutics stock logo

ZyVersa Therapeutics NASDAQ:ZVSA

$0.67 -0.11 (-13.94%)
As of 09:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.